If your prescriber has recommended a shorter interval, follow their guidance
Buse JB, Garber A, Rosenstock J, Schmidt WE, Brett JH, Videbaek N, Holst J, Nauck M (2011) Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials
It consists of a series of protein complexes (I, II, III, IV) and electron carriers that facilitate the oxidation of electrons derived from nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (FADH 2 ) through a series of biochemical reactions, ultimately reducing molecular oxygen (O 2 )
Some claim however that it can accumulate into the skin and protect you up to several days after application